ClinicalTrials.gg
Not yet recruitingNCT07886385GSE_PKUpdated Oct 21, 2026

Differential Absorption Kinetics of Grape Seed Extract Polyphenols

An interventional study of MN-BP Grape Seed Extract and Commercially Available Grape Seed Extract in Healthy Adults, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology · Not applicable, Interventional, and Basic science

Updated Oct 21, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Grape seed extracts (GSEs) contain (poly)phenols that vary in their degree of polymerization, which may lead to differences in absorption, metabolism, and biological efficacy. This pilot study will evaluate how GSEs with varying degrees of polymerization are absorbed, cleared, and metabolized in healthy adults.

Two separate pilot studies will be conducted. Study 1 will evaluate MN-BP compared to another commercially available GSE. Study 2 will evaluate four next-generation (Gen 2) GSE preparations enriched in monomers, oligomers, polymers, or a mixture. Blood and urine samples will be collected at multiple time points following GSE consumption to assess bioavailability and metabolic profiles of the different GSE preparations.

Read the detailed description

Grape seed extracts (GSEs) are widely studied for their potential cardiometabolic health benefits, largely due to their high (poly)phenol content. GSEs can differ substantially in their (poly)phenol composition, particularly in their degree of polymerization, which may lead to differences in absorption, metabolism, and biological efficacy. GSE (poly)phenols include compounds ranging from monomers, such as catechin and epicatechin, to oligomeric and polymeric compounds. Monomeric forms are absorbed in the small intestine, whereas oligomeric and polymeric forms have limited direct absorption and may undergo microbial metabolism in the colon, producing smaller metabolites that can be absorbed systemically. This pilot study will evaluate the absorption and clearance kinetics and metabolite profiles of GSEs with varying degrees of polymerization in healthy adults.

STUDY DESIGN

This study consists of two separate pilot studies using a randomized, double-blinded, crossover design.Study 1 will compare MN-BP with another commercially available GSE. Study 2 will evaluate next-generation (Gen 2) GSE preparations enriched in monomers, oligomers, polymers, or a mixture. Participants will receive different GSE interventions during separate intervention periods according to a randomized sequence. A washout period will occur between interventions to minimize potential carryover effects. Both studies will follow similar study procedures; the GSE interventions will differ.

SCREENING VISIT

Participants eligibility for the study will be determined based on the study inclusion and exclusion criteria. During the Screening Visit, the following general measurements will be obtained: height, weight, body composition, waist circumference, blood pressure, heart rate, and body temperature. Fasting blood glucose will be measured using a finger prick. A pregnancy test will also be performed when applicable. Participants will complete demographic, health, and medication questionnaires. They will be asked to provide information about their demographics, health and medical history, medications, dietary habits, and other information relevant to determining study eligibility. Based on the results of the fasting finger-prick blood glucose, questionnaires, physical measurements, and evaluation of general health, participants who meet the eligibility criteria may be invited to continue in the study.

PRE-STUDY VISIT

The Pre-Study Visit may be performed on the same day as the Screening Visit. This visit will last approximately 45 minutes to 1 hour. Study staff will provide detailed instructions about the study procedures and how participants should prepare for each study day. Participants will be trained on study procedures, including foods to avoid, medications and supplements to avoid, food diary recording and overnight fasting. Study dates will be scheduled, and participants will receive a study booklet containing the study calendar and study instructions. Participants will also be provided with a frozen dinner to consume the day before the next intervention visit. If participants are taking medications or supplements that do not interfere with the study or have been approved by the study staff, they will continue taking them as instructed by their healthcare provider and record them in their diary. Study staff will provide instructions regarding foods and supplements that are allowed or should be avoided during the study.

STUDY DAY VISITS

At the beginning of each intervention visit, study staff will collect study materials from the participant, including the participant's diary, and provide the 24-hour dietary recall (ASA24). Study staff will confirm that the participant has followed the required study-day preparation instructions. Fasting blood glucose will be checked by finger prick to verify usual fasting glucose. Before beginning the intervention, anthropometric measurements, including weight, waist circumference, and body composition, will be obtained. Vital signs, including blood pressure, heart rate, and body temperature, will also be measured.

GSE ADMINISTRATION AND BLOOD COLLECTION

Participants will meet with a Licensed Health Care Provider for blood sample collection. An intravenous catheter (IV) will be placed in the participant's arm or hand to allow multiple blood samples to be collected during the study visit while minimizing repeated needle sticks. If there is difficulty obtaining blood through the IV catheter, participants may be asked whether they are comfortable with individual blood collections using a butterfly needle. There will be eight blood draws over approximately 8hours during the intervention visit. Immediately after catheter placement and collection of the first blood sample, participants will receive the assigned GSE treatment to take with water. The next blood sample will be collected approximately 1 hour later.Serial blood samples will be collected throughout the study period to assess GSE-derived parent (poly)phenolic compounds and their metabolites and characterize their absorption over time.

MEALS DURING THE STUDY VISIT

Participants will receive standardized low-(poly)phenol meals during the intervention visit. Breakfast will be provided during the morning portion of the study visit, and a low-(poly)phenol lunch will also be provided during the visit.After completion of the scheduled blood and urine collections, participants will be provided with a dinner meal to take home.

URINE COLLECTION

Urine samples will be collected at multiple time points according to the study schedule. Participants will be provided with water during the study visit, and the amount of water consumed will be recorded. Blood and urine samples will subsequently be used to characterize parent (poly)phenolic compounds and their metabolites and evaluate the absorption, clearance, bioavailability, and metabolic profiles of the GSE interventions.

24-HOUR FOLLOW-UP VISIT

After completing the intervention-day procedures and consuming the provided dinner, participants will return to the clinic the following day in a fasting state, consuming only water during the fasting period. At the follow-up visit, a fasting blood sample and urine sample will be collected after taking fasting glucose through finger prick and blood pressure.

These samples will provide the later time-point measurements needed to evaluate the absorption and clearance of GSE-derived (poly)phenolic compounds and their metabolites.

WASHOUT AND CROSSOVER

Following completion of one intervention period, participants will undergo a washout period of 7-10 days before the next intervention to minimize potential carryover effects. Participants will then repeat the required dietary preparation and study-day procedures before receiving the next GSE intervention according to their randomized crossover sequence.

The intervention procedures-including pre-study dietary restrictions, anthropometric and vital-sign measurements, GSE administration, serial blood collection, standardized low-(poly)phenol meals, urine collection, and the fasting follow-up visit-will be repeated for the subsequent GSE interventions.

SAMPLE ANALYSIS

Venous blood will be collected in EDTA tubes, and plasma will be separated. Blood and urine samples will be stored at -80°C until analysis. GSE-derived (poly)phenols and their metabolites will be characterized in the collected plasma and urine samples. The samples will be analyzed using ultra-high-performance liquid chromatography and mass spectrometry (UHPLC-MS).

The resulting concentration-time profiles will be used to evaluate absorption and clearance kinetics, bioavailability, and metabolic profiles of the different GSE preparations.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology is the lead sponsor of 61 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women, 18-45 years of age
  • Willing to maintain their usual dietary habits with low (poly)phenol intake and physical activity patterns 3 days before the study visits. Willing and able to comply with all study requirements, including:

    • Consumption of standardized low-(poly)phenol meals and study treatments.
    • Completion of all scheduled clinic visits and biological sample collections.
    • Compliance with dietary restrictions and study instructions.
  • Able to provide informed consent
  • Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study; able to come to the clinic up to 5 times during the study
  • Able to maintain usual physical activity pattern
  • Able to avoid/abstain from alcohol/and vigorous physical activity for 24 hours prior to and during the study visit

Exclusion criteria

Exclusion Criteria:

  • Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions
  • Fasting blood sugar >125 mg/dL
  • Men and women with blood pressure >160 mmHg (systolic) / 100 mmHg (diastolic) at the screening visit
  • Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year
  • Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years
  • Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints
  • Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.)
  • Men and women who are not weight stable (+/-10lbs in previous 2 months)
  • Men and women who have excessive use of drugs or alcohol (i.e.., addictions) within the past 2 years
  • Men and women with documented physical or mental disease/condition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study
  • Women who are lactating
  • Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI.
  • Has used antibiotics within the previous 2 months
  • History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional
  • Excessive coffee and tea consumers (> 4 cups/d)
  • Donated blood within the last 3 months
  • Women who are taking an unstable dose and brand of hormonal contraceptives and/or a stable dose and brand for less than 6 months
  • Unusual working hours i.e., working overnight (e.g., 3rd shift)
  • Participant who is a current smoker and unable to be smoke-free for 24 h.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Study 1 - MN-BP and Commercially Available GSE

    Participants in Study 1 will receive MN-BP and another commercially available grape seed extract (GSE) during separate intervention periods in a randomized, double-blinded, crossover design. GSEs will be administered in capsule form.

    Dietary Supplement: MN-BP Grape Seed Extract · Dietary Supplement: Commercially Available Grape Seed Extract

  • Experimental
    Study 2 - Gen 2 GSE Preparations

    Participants in Study 2 will receive next-generation (Gen 2) grape seed extract (GSE) preparations enriched in monomers, oligomers, polymers, or a mixture during separate intervention periods in a randomized, double-blinded, crossover design

    Dietary Supplement: Gen 2 GSE - Monomer-Enriched · Dietary Supplement: Gen 2 GSE - Oligomer-Enriched · Dietary Supplement: Gen 2 GSE - Polymer-Enriched · Dietary Supplement: Gen 2 GSE - Mixture

Interventions

  • Dietary supplementMN-BP Grape Seed Extract

    Study 1 - MN-BP and Commercially Available GSE

  • Dietary supplementCommercially Available Grape Seed Extract

    Study 1 - MN-BP and Commercially Available GSE

  • Dietary supplementGen 2 GSE - Monomer-Enriched

    Study 2 - Gen 2 GSE Preparations

  • Dietary supplementGen 2 GSE - Oligomer-Enriched

    Study 2 - Gen 2 GSE Preparations

  • Dietary supplementGen 2 GSE - Polymer-Enriched

    Study 2 - Gen 2 GSE Preparations

  • Dietary supplementGen 2 GSE - Mixture

    Study 2 - Gen 2 GSE Preparations

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of GSE-derived (poly)phenols and their metabolites

    Plasma concentrations of parent GSE-derived (poly)phenolic compounds and their metabolites will be measured using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) at different time points following each GSE intervention.

    Time frame: Baseline through 24 hours after GSE consumption

  2. Urinary concentrations of GSE-derived (poly)phenols and their metabolites

    Urine samples will be analyzed using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to quantify GSE-derived (poly)phenolic compounds and their metabolites following each GSE intervention

    Time frame: Baseline through 24 hours after GSE consumption

Secondary outcomes

  1. Bioavailability of GSE-derived (poly)phenols and their metabolites

    GSE-derived (poly)phenolic compounds and their metabolites will be identified and quantified in plasma and urine using ultra-high-performance liquid chromatography and mass spectrometry (UHPLC-MS).

    Time frame: Baseline through 24 hours after GSE consumption

  2. Plasma metabolite profiles following GSE consumption

    GSE-derived metabolites will be identified in plasma using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to characterize the metabolite profiles associated with the different GSE preparations.

    Time frame: Baseline through 24 hours after each GSE intervention

  3. Urinary metabolite profiles following GSE consumption

    GSE-derived metabolites will be identified in urine using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) to characterize the urinary metabolite profiles associated with the different GSE preparations

    Time frame: Baseline through 24 hours after each GSE intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07886385
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Indika Edirisinghe
Contact
iedirisi@illinoistech.edu
708-563-8178
Chelsesa Preiss
Contact
cpreiss@illinoistech.edu
303-567-5308
Britt Burton-Freeman
principal investigator · 708-563-8276

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion